TEST BANK FOR Pharmacotherapeutics for Advanced Practice: A Practical Approach Fifth Edition by Virginia Poole Arcangelo ISBN: 978-1975160593 COMPLETE GUIDE ALL CHAPTERS COVERED 100% VERIFIED A+ GRADE ASSURED!!!!!NEW LATEST UPDATE!!!!!

, x# x
lOM oARc



# x#
4
PSD| 301380




lOM x# x# x#
oARc PSD| 3013804




Chapter 1 Issues for the Practitioner in Drug Therapy
x# x# x# x# x# x# x# x#




MULTIPLE CHOICE x#




1. Nurse practitioner prescriptive authority is regulated by:
x# x# x# x# x# x#


A. The National Council of State Boards of Nursing
x# x# x# x# x# x# x#


B. The U.S. Drug Enforcement Administration
x# x# x# x#


C. The State Board of Nursing for each state
x# x# x# x# x# x# x#


D. The State Board of Pharmacy
x# x# x# x#




ANS: x # C PTS: 1 x#




2. Physician Assistant (PA) prescriptive authority is regulated by:
x# x# x# x# x# x# x#


A. The National Council of State Boards of Nursing
x# x# x# x# x# x# x#


B. The U.S. Drug Enforcement Administration
x# x# x# x#


C. The State Board of Nursing
x# x# x# x#


D. The State Board of Medical Examiners
x# x# x# x# x#




ANS: x # D PTS: 1 x#




3. Clinical judgment in prescribing includes:
x# x# x# x#


A. Factoring in the cost to the patient of the medication prescribed
x# x# x# x# x# x# x# x# x# x#


B. Always prescribing the newest medication available for the disease process
x# x# x# x# x# x# x# x# x#


C. Handing out drug samples to poor patients
x# x# x# x# x# x#


D. Prescribing all generic medications to cut costs
x# x# x# x# x# x#




ANS: x # A PTS: 1 x#




4. Criteria for choosing an effective drug for a disorder include:
x# x# x# x# x# x# x# x# x#


A. Asking the patient what drug they think would work best for them
x# x# x# x# x# x# x# x# x# x# x#


B. Consulting nationally recognized guidelines for disease management
x# x# x# x# x# x #


C. Prescribing medications that are available as samples before writing a prescription
x# x# x# x# x# x# x# x# x# x#


D. Following U.S. Drug Enforcement Administration (DEA) guidelines for
x# x# x# x# x# x# x# x


prescribing
#




ANS: x # B PTS: 1 x#




5. Nurse practitioner practice may thrive under health-care reform due to:
x# x# x# x# x# x# x# x# x#


A. The demonstrated ability of nurse practitioners to control costs and improve patient
x# x# x# x# x# x# x# x# x# x# x#


outcomes
x #


B. The fact that nurse practitioners will be able to practice independently
x# x# x# x# x# x# x# x# x# x#


C. The fact that nurse practitioners will have full reimbursement under health-
x# x# x# x# x# x# x# x# x# x#


care reform x #


D. The ability to shift accountability for Medicaid to the state level
x# x# x# x# x# x# x# x# x# x#




ANS: x # A PTS: 1 x#

, x# x
lOM oARc



# x#
4
PSD| 301380




Chapter 2.Pharmacokinetic Basis of Therapeutics and Pharmacodynamic
x# x# x# x# x# x#




MULTIPLE CHOICE x#




1. A patient’s nutritional intake and lab work reflects hypoalbuminemia. This is critical t
x# x# x# x# x# x# x# x# x# x# x# x#


o prescribing because:
x# x #


A. Distribution of drugs to target tissue may be affected x# x# x# x# x# x# x# x#


B. The solubility of the drug will not match the site of absorption
x# x# x# x# x# x# x# x# x# x# x#


C. There will be less free drug available to generate an effect
x# x# x# x# x# x# x# x# x# x#


D. Drugs bound to albumin are readily excreted by the kidney
x# x# x# x# x# x# x# x# x#




ANS: x # A PTS: 1 x#




2. Drugs that have a significant first-pass effect:
x# x# x# x# x# x#


A. Must be given by the enteral (oral) route only
x# x# x# x# x# x# x# x#


B. Bypass the hepatic circulation x# x# x#


C. Are rapidly metabolized by the liver and may have little if any desired action
x# x# x# x# x# x# x# x# x# x# x# x# x#


D. Are converted by the liver to more active and fat-soluble forms
x# x# x# x# x# x# x# x# x# x#




ANS: x # C PTS: 1 x#




3. The route of excretion of a volatile drug will likely be:
x# x# x# x# x# x# x# x# x# x#


A. The kidneys x#


B. The lungs x#


C. The bile and feces x# x# x#


D. The skin x#




ANS: x # B PTS: 1 x#




4. Medroxyprogesterone (Depo Provera) is prescribed IM to create a storage reservoir of t
x# x# x# x# x# x# x# x# x# x# x# x#


he drug. Storage reservoirs:
x# x# x#


A. Assure that the drug will reach its intended target tissue
x# x# x# x# x# x# x# x# x#


B. Are the reason for giving loading doses
x# x# x# x# x# x#


C. Increase the length of time a drug is available and active
x# x# x# x# x# x# x# x# x# x#


D. Are most common in collagen tissues
x# x# x# x# x#




ANS: x # C PTS: 1 x#




5. The NP chooses to give cephalexin every 8 hours based on knowledge of the drug’s:
x# x# x# x# x# x# x# x# x# x# x# x# x# x#


A. Propensity to go to the target receptor x# x# x# x# x# x#


B. Biological half-life x #


C. Pharmacodynamics
D. Safety and side effects x# x# x#




ANS: x # B PTS: 1 x#




6. Azithromycin dosing requires the first day’s dose be twice those of the other 4 days of t
x# x# x# x# x# x# x# x# x# x# x# x# x# x# x# x#


he prescription. This is considered a loading dose. A loading dose:
x# x# x# x# x # x# x # x # x# x #


A. Rapidly achieves drug levels in the therapeutic range
x# x# x# x# x# x# x#


B. Requires four to five half-lives to attain
x# x# x# x# x# x#


C. Is influenced by renal function
x# x# x# x#

, x# x
lOM oARc



# x#
4
PSD| 301380




D. Is directly related to the drug circulating to the target tissues
x# x# x# x# x# x# x# x# x# x#




ANS: x # A PTS: x # x # 1

7. The point in time on the drug concentration curve that indicates the first sign of a therape
x# x# x# x# x# x# x# x# x# x# x# x# x# x# x# x#


utic effect is the:
x# x# x#


A. Minimum adverse effect level x# x# x#


B. Peak of action x# x#


C. Onset of action x# x#


D. Therapeutic range x#




ANS: x # C PTS: 1 x#




8. Phenytoin requires a trough level be drawn. Peak and trough levels are done:
x# x# x# x# x# x# x# x# x# x# x# x#


A. When the drug has a wide therapeutic range
x# x# x# x# x# x# x#


B. When the drug will be administered for a short time only
x# x# x# x# x# x# x# x# x# x#


C. When there is a high correlation between the dose and saturation of receptor sites
x# x# x# x# x# x# x# x# x# x# x# x# x#


D. To determine if a drug is in the therapeutic range
x# x# x# x# x# x# x# x# x#




ANS: x # D PTS: 1 x#




9. A laboratory result indicates the peak level for a drug is above the minimum toxi
x# x# x# x# x# x# x# x# x# x# x# x# x# x#


c concentration. This means that the:
x# x# x# x# x#


A. Concentration will produce therapeutic effects x# x# x# x #


B. Concentration will produce an adverse response x# x# x# x# x#


C. Time between doses must be shortened
x# x# x# x# x#


D. Duration of action of the drug is too long
x# x# x# x# x# x# x# x#




ANS: x # B PTS: 1 x#




10. Drugs that are receptor agonists may demonstrate what property?
x# x# x# x# x# x# x# x#


A. Irreversible binding to the drug receptor site x# x# x# x# x# x#


B. Up-regulation with chronic use x# x# x#


C. Desensitization or down-regulation with continuous use x# x# x # x# x#


D. Inverse relationship between drug concentration and drug action
x# x# x# x# x# x# x#




ANS: x # C PTS: 1 x#




11. Drugs that are receptor antagonists, such as beta blockers, may cause:
x# x# x# x# x# x# x# x# x# x#


A. Down-regulation of the drug receptor x# x# x# x#


B. An exaggerated response if abruptly discontinued
x# x# x# x# x#


C. Partial blockade of the effects of agonist drugs
x# x# x# x# x# x# x#


D. An exaggerated response to competitive drug agonists
x# x# x# x# x# x#




ANS: x # B PTS: 1 x#




12. Factors that affect gastric drug absorption include:
x# x# x# x# x# x#


A. Liver enzyme activityx# x#


B. Protein-binding properties of the drug molecule x# x# x# x# x#


C. Lipid solubility of the drug
x# x# x# x#


D. Ability to chew and swallow x# x# x# x#




ANS: x # C PTS: 1 x#